000756.SZ
新华制药
SZSE · Healthcare · C 制造业 · CN
CNY 13.17
−2.95%Year over year
Reported trailing growth
- Revenue
- +3.9%
- EBITDA
- —
- EBIT
- -33.0%
- EPS
- -38.1%
- Free cash flow
- +144.1%
- Operating cash flow
- +20.9%
Forward estimates
Based on analyst estimates
- Revenue
- -11.4%
- EBITDA
- +48.9%
- EPS
- +159.0%
Three-year CAGR
- Revenue
- +5.3%
- EBITDA
- -0.4%
- EBIT
- -8.6%
- Net income
- -11.0%
- EPS
- -12.2%
- Free cash flow
- -6.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026